United Therapeutics (NASDAQ:UTHR) Given New $212.00 Price Target at JPMorgan Chase & Co.


Share on StockTwits

United Therapeutics (NASDAQ:UTHR) had its price target hoisted by equities research analysts at JPMorgan Chase & Co. from $185.00 to $212.00 in a report issued on Thursday, The Fly reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 10.94% from the stock’s current price.

Several other analysts have also issued reports on the company. LADENBURG THALM/SH SH boosted their target price on United Therapeutics from $151.00 to $199.00 and gave the company a “buy” rating in a research note on Wednesday, January 20th. Cowen boosted their price objective on United Therapeutics from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Wednesday, January 20th. Credit Suisse Group boosted their price objective on United Therapeutics from $169.00 to $196.00 and gave the company an “outperform” rating in a research note on Monday, March 1st. Oppenheimer boosted their price objective on United Therapeutics from $200.00 to $275.00 and gave the company an “outperform” rating in a research note on Tuesday, February 16th. Finally, Wedbush boosted their price objective on United Therapeutics from $255.00 to $260.00 and gave the company an “outperform” rating in a research note on Thursday, February 25th. They noted that the move was a valuation call. Eight investment analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and a consensus target price of $208.13.

Shares of UTHR opened at $191.10 on Thursday. The firm has a market cap of $8.51 billion, a PE ratio of 18.08 and a beta of 0.52. The stock’s fifty day moving average price is $170.31 and its two-hundred day moving average price is $147.53. The company has a debt-to-equity ratio of 0.24, a current ratio of 7.22 and a quick ratio of 6.88. United Therapeutics has a 1 year low of $94.09 and a 1 year high of $200.00.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Tuesday, February 23rd. The biotechnology company reported $2.19 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $2.96 by ($0.77). The firm had revenue of $384.90 million during the quarter, compared to the consensus estimate of $362.04 million. United Therapeutics had a net margin of 33.25% and a return on equity of 15.48%. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.96 earnings per share. Sell-side analysts anticipate that United Therapeutics will post 12.55 earnings per share for the current fiscal year.

In other United Therapeutics news, Director Judy D. Olian sold 4,207 shares of the company’s stock in a transaction dated Thursday, April 1st. The stock was sold at an average price of $184.96, for a total value of $778,126.72. Following the transaction, the director now directly owns 9,997 shares in the company, valued at approximately $1,849,045.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Judy D. Olian sold 2,103 shares of the company’s stock in a transaction dated Wednesday, March 17th. The stock was sold at an average price of $170.00, for a total value of $357,510.00. Following the completion of the transaction, the director now owns 7,893 shares of the company’s stock, valued at $1,341,810. The disclosure for this sale can be found here. 10.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. JJJ Advisors Inc. boosted its holdings in shares of United Therapeutics by 775.0% in the 4th quarter. JJJ Advisors Inc. now owns 245 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 217 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of United Therapeutics in the 4th quarter worth about $43,000. Signaturefd LLC boosted its holdings in shares of United Therapeutics by 54.0% in the 4th quarter. Signaturefd LLC now owns 308 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 108 shares in the last quarter. Parallel Advisors LLC boosted its holdings in shares of United Therapeutics by 42.2% in the 4th quarter. Parallel Advisors LLC now owns 590 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 175 shares in the last quarter. Finally, Veriti Management LLC purchased a new position in shares of United Therapeutics in the 4th quarter worth about $135,000. Hedge funds and other institutional investors own 90.09% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Story: Calculate Your Return on Investment (ROI)

The Fly

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.